前列腺癌的反应监测、预测方法、分期及影像学检查
Monitoring response, prediction methodology, staging, and imaging in prostate cancer.
作者信息
Pomerantz David, Vogelzang Nicholas
出版信息
Rev Urol. 2006;8 Suppl 2(Suppl 2):S30-4.
Abstract
The predictive values of various tests and examinations are assessed as they relate to prostate cancer progression and treatment. The usefulness of post-treatment biopsy specimens is greatest 2 years after radiation therapy completion. Gleason grading is not reliable in the setting of hormonal ablation therapy. For patients with extracapsular extension, the survival curves separate depending on whether positive or negative surgical margins are obtained. Prostate-specific antigen doubling time is increasingly used as an indicator of disease recurrence after local therapy and prostate cancer-specific survival.
摘要
对各种检测和检查的预测价值进行评估，评估内容涉及前列腺癌的进展和治疗。治疗后活检标本在放疗结束2年后的作用最大。在激素消融治疗的情况下，Gleason分级不可靠。对于有包膜外侵犯的患者，生存曲线根据手术切缘是阳性还是阴性而分开。前列腺特异性抗原倍增时间越来越多地被用作局部治疗后疾病复发和前列腺癌特异性生存的指标。
相似文献
1
Monitoring response, prediction methodology, staging, and imaging in prostate cancer.前列腺癌的反应监测、预测方法、分期及影像学检查
Rev Urol. 2006;8 Suppl 2(Suppl 2):S30-4.
2
The role of transrectal ultrasound-guided biopsy-based staging, preoperative serum prostate-specific antigen, and biopsy Gleason score in prediction of final pathologic diagnosis in prostate cancer.经直肠超声引导下活检分期、术前血清前列腺特异性抗原及活检Gleason评分在前列腺癌最终病理诊断预测中的作用。
Urology. 1995 Aug;46(2):205-12. doi: 10.1016/s0090-4295(99)80195-2.
3
Enhancing the efficacy of radical prostatectomy in locally advanced prostate cancer.提高局部晚期前列腺癌根治性前列腺切除术的疗效。
Urol Int. 1998;60 Suppl 2:2-10; discussion 35. doi: 10.1159/000056545.
4
The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.根治性前列腺切除术后前列腺特异性抗原持续存在对预测淋巴结阳性前列腺癌患者临床进展和癌症特异性死亡率的作用。
Eur Urol. 2016 Jun;69(6):1142-8. doi: 10.1016/j.eururo.2015.12.010. Epub 2015 Dec 31.
5
Percentage of cancer on biopsy cores accurately predicts extracapsular extension and biochemical relapse after radical prostatectomy for T1-T2 prostate cancer.活检组织芯中癌症的百分比可准确预测T1-T2期前列腺癌根治性前列腺切除术后的包膜外侵犯和生化复发。
Eur Urol. 2000 Apr;37(4):449-55. doi: 10.1159/000020167.
6
Preoperative prediction of neurovascular bundle involvement of localized prostate cancer by combined T2 and diffusion-weighted imaging of magnetic resonance imaging, number of positive biopsy cores, and Gleason score.通过磁共振成像的T2加权和扩散加权成像、阳性活检核心数量以及Gleason评分对局限性前列腺癌神经血管束受累进行术前预测。
Asian Pac J Cancer Prev. 2011;12(4):909-13.
7
8
A multivariable analysis of clinical factors predicting for pathological features associated with local failure after radical prostatectomy for prostate cancer.对前列腺癌根治性前列腺切除术后与局部复发相关的病理特征的临床预测因素进行多变量分析。
Int J Radiat Oncol Biol Phys. 1994 Sep 30;30(2):293-302. doi: 10.1016/0360-3016(94)90007-8.
9
The presence of positive surgical margins in patients with organ-confined prostate cancer results in biochemical recurrence at a similar rate to that in patients with extracapsular extension and PSA ≤ 10 ng/ml.在局限于器官的前列腺癌患者中，如果存在阳性切缘，则生化复发的发生率与包膜外侵犯和 PSA≤10ng/ml 的患者相似。
Urol Oncol. 2014 Jan;32(1):32.e17-25. doi: 10.1016/j.urolonc.2012.11.021. Epub 2013 Feb 19.
10
Importance of Local Control in Early-Stage Prostate Cancer: Outcomes of Patients With Positive Post-Radiation Therapy Biopsy Results Treated in RTOG 9408.局部控制在早期前列腺癌中的重要性：放射治疗肿瘤学组（RTOG）9408研究中放疗后活检结果为阳性患者的结局
Int J Radiat Oncol Biol Phys. 2015 Jul 15;92(4):863-73. doi: 10.1016/j.ijrobp.2015.03.017. Epub 2015 Mar 25.
本文引用的文献
1
Mapping of nodal disease in locally advanced prostate cancer: rethinking the clinical target volume for pelvic nodal irradiation based on vascular rather than bony anatomy.局部晚期前列腺癌的淋巴结疾病图谱：基于血管而非骨骼解剖结构重新思考盆腔淋巴结照射的临床靶区
Int J Radiat Oncol Biol Phys. 2005 Nov 15;63(4):1262-9. doi: 10.1016/j.ijrobp.2005.07.952.
2
Retrospective analysis of prostate cancer patients with implanted gold markers using off-line and adaptive therapy protocols.使用离线和自适应治疗方案对植入金标记物的前列腺癌患者进行回顾性分析。
Int J Radiat Oncol Biol Phys. 2005 Sep 1;63(1):123-33. doi: 10.1016/j.ijrobp.2005.02.013.
3
Surrogate end point for prostate cancer specific mortality in patients with nonmetastatic hormone refractory prostate cancer.非转移性激素难治性前列腺癌患者前列腺癌特异性死亡率的替代终点
J Urol. 2005 May;173(5):1572-6. doi: 10.1097/01.ju.0000157569.59229.72.
4
Survival in prostate carcinoma--outcomes from a prospective, population-based cohort of 8887 men with up to 15 years of follow-up: results from three countries in the population-based National Prostate Cancer Registry of Sweden.前列腺癌的生存率——来自一个前瞻性、基于人群的队列研究结果，该队列包含8887名男性，随访长达15年：瑞典全国基于人群的前列腺癌登记处三个国家的结果
Cancer. 2005 Mar 1;103(5):943-51. doi: 10.1002/cncr.20855.
5
Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results.3478例连续性患者接受耻骨后根治性前列腺切除术后的癌症进展和生存率：长期结果
J Urol. 2004 Sep;172(3):910-4. doi: 10.1097/01.ju.0000134888.22332.bb.
6
Validation of increasing prostate specific antigen as a predictor of prostate cancer death after treatment of localized prostate cancer with surgery or radiation.前列腺特异性抗原升高作为局限性前列腺癌手术或放疗后前列腺癌死亡预测指标的验证。
J Urol. 2004 Jun;171(6 Pt 1):2221-5. doi: 10.1097/01.ju.0000124381.93689.b4.
7
Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure.前列腺特异性抗原失败后挽救性激素治疗的前列腺癌特异性死亡率的中间终点。
J Natl Cancer Inst. 2004 Apr 7;96(7):509-15. doi: 10.1093/jnci/djh086.
8
Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02.前列腺局部晚期癌新辅助激素细胞减灭术及放疗后长期辅助性雄激素剥夺的Ⅲ期试验：放射治疗肿瘤学组方案92 - 02
J Clin Oncol. 2003 Nov 1;21(21):3972-8. doi: 10.1200/JCO.2003.11.023.
9
Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.在激素难治性前列腺癌男性患者中使用氢化可的松联合或不联合米托蒽醌：癌症与白血病B组9182研究结果
J Clin Oncol. 1999 Aug;17(8):2506-13. doi: 10.1200/JCO.1999.17.8.2506.
10
Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial.
J Clin Oncol. 1999 Oct;17(10):3160-6. doi: 10.1200/JCO.1999.17.10.3160.
Zotero 插件